Skip to main content
. Author manuscript; available in PMC: 2015 Jul 21.
Published in final edited form as: Curr Biol. 2014 Jul 3;24(14):1573–1583. doi: 10.1016/j.cub.2014.06.004

Figure 5. Nrf1 nuclear translocation with low, but not high concentrations, of proteasome inhibitors requires its N-terminal processing.

Figure 5

(A) HEK293A cells overexpressing Nrf1-HA were treated with BTZ (10nM), Epox (50nM), or MG132 (10µM) for 16h, and Nrf1-HA localization was detected by HA immunostaining. Nuclear translocation of Nrf1-HA occurred after treatment with BTZ and Epox, but not MG132. (B) After HEK293A cells overexpressing Nrf1-HA or HA-Nrf1 were treated with BTZ (10nM) or Epox (20nM) for 16h, HA immunostaining detected Nrf1-HA, but not HA-Nrf1, in the nuclei of the BTZ or Epox-treated cells. (C) HEK293A cells overexpressing Nrf1-HA or HA-Nrf1 were treated with Epox (20 or 500nM) for 16h. Nrf1 antibody, but not the HA antibody, could detect nuclear HA-Nrf1 upon 20nM Epox treatment. 500nM Epox, like 10µM MG132, did not induce Nrf1 nuclear translocation. All scale bars are 50 µm.